Jaal Jana, Dörr Wolfgang
Department of Radiotherapy and Radiation Oncology, University of Technology of Dresden, Dresden, Germany.
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):528-33. doi: 10.1016/j.ijrobp.2007.05.074.
To determine the effect of Palifermin (rHuKGF) on acute and late radiation effects in mouse urinary bladder.
Graded radiation doses were applied on day 0. Single subcutaneous injections of Palifermin (15 mg/kg) were given on day -2 or day +2. Changes in bladder function (i.e., a reduction in bladder volume by >or=50% of the individual preirradiation value) were assessed by cystometry.
Early changes in mouse bladder after irradiation occur in two phases. In the first early phase, a single injection of Palifermin on day -2 increased the ED(50) (dose associated with a positive bladder response in 50% of the mice) from 20.0 +/- 3.3 Gy to 27.1 +/- 6.9 Gy (p < .0051). Palifermin given on day +2 was not beneficial. No significant effects of Palifermin were seen in the second early phase. However, Palifermin administration before, but not after, irradiation, also modified late radiation effects, with an ED50 of 22.2 +/- 4.8 Gy compared with 16.2 +/- 4.9 Gy in control animals (p < .0187).
Initial early functional changes in the mouse urinary bladder after irradiation as well as late effects can be significantly reduced by a single administration of Palifermin before irradiation.
确定帕利夫明(重组人角质形成细胞生长因子)对小鼠膀胱急性和晚期辐射效应的影响。
于第0天给予分级辐射剂量。在第 -2天或第 +2天单次皮下注射帕利夫明(15毫克/千克)。通过膀胱测压法评估膀胱功能的变化(即膀胱体积减少至个体照射前值的≥50%)。
照射后小鼠膀胱的早期变化分两个阶段出现。在第一个早期阶段,于第 -2天单次注射帕利夫明使半数有效剂量(ED50,即50%的小鼠出现膀胱阳性反应的相关剂量)从20.0±3.3 Gy增加至27.1±6.9 Gy(p <.0051)。在第 +2天给予帕利夫明并无益处。在第二个早期阶段未观察到帕利夫明显著的效应。然而,在照射前而非照射后给予帕利夫明,也改变了晚期辐射效应,其半数有效剂量为22.2±4.8 Gy,而对照动物为16.2±4.9 Gy(p <.0187)。
照射前单次给予帕利夫明可显著减轻照射后小鼠膀胱最初的早期功能变化以及晚期效应。